KEZAR LIFE SCIENCES, INC.Equity Incentive Plan • May 24th, 2018 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • Delaware
Unless otherwise defined herein, the terms defined in the 2015 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement – Early Exercise (the “Option Agreement”).
KEZAR LIFE SCIENCES, INC.Equity Incentive Plan • May 24th, 2018 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • Delaware
Unless otherwise defined herein, the terms defined in the 2015 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
EXCLUSIVE LICENSE AGREEMENT by and between ONYX THERAPEUTICS, INC. and KEZAR LIFE SCIENCES, INC. Dated as of June 11, 2015Exclusive License Agreement • May 24th, 2018 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of June 11, 2015 (the “Effective Date”) by and between ONYX THERAPEUTICS, INC., a Delaware corporation having an address at 249 E. Grand Avenue, South San Francisco, CA 94080 (“ONYX”), and KEZAR LIFE SCIENCES, INC., a Delaware corporation having an address at 391 Carl Street, San Francisco, CA 94117 (“KEZAR”). KEZAR and ONYX are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
